Initiating chemotherapy usually requires a delay of more than 4 weeks after surgically resecting colorectal cancer. However, there is little evidence regarding the required delay interval. We have previously reported a pilot study to determine the safety and feasibility of early initiation of chemotherapy after resecting primary colorectal cancer with distant metastases. We aimed to determine the safety and efficacy of early initiation of chemotherapy after resecting colorectal cancer with distant metastases. This phase II study (trial number UMIN000006310) was a prospective, single-arm trial. A total of 20 patients (men, 15 and women, 5) were enrolled. They underwent XELOX therapy (130 mg/m 2 oxaliplatin on day 1+1000 mg/m 2 capecitabine twice daily on days 1-4) on postoperative day 7 and XELOX+bevacizumab (7.5 mg/kg bevacizumab on day 1) after the second chemotherapy cycle. Baseline characteristics included a median age of 64 (range, 43-72) years. Surgical procedures included right hemicolectomy in six patients, sigmoidectomy in three, anterior resection in five, and Hartmann procedure in six.
| INTRODUCTION
The National Comprehensive Cancer Network recommends that patients with metastatic colorectal cancer (CRC) undergo primary tumor resection if they have impending obstruction, bowel obstruction, or potentially resectable metastases. There is no doubt that resection or stoma placement is mandatory before starting systemic chemotherapy among patients with severe intestinal symptoms. [1] [2] [3] Palliative resection of primary tumors reportedly improves systemic chemotherapy efficacy 4 and prolongs time to treatment failure. 5 In many cases, it is not possible for patients to continue chemotherapy because of complications, such as bleeding, perforation and bowel obstruction, if chemotherapy is started without surgical resection of the symptomatic primary tumor. Therefore, surgical resection of the primary tumor is apparently necessary to utilize chemotherapy with few complications. However, surgical resection may delay chemotherapy initiation. 6 In general, a post-surgical period longer than 4 weeks is standard until starting chemotherapy, 6, 7 such as treatment with folinic acid, fluorouracil (5-FU), and oxaliplatin; folinic acid, 5-FU, and irinotecan; and capecitabine and oxaliplatin (XELOX).
However, there is no positive evidence for this delay. In stage III disease, the time to start adjuvant therapy is an important prognostic factor for both colon and rectal cancers. [8] [9] [10] [11] Early adjuvant therapy initiation is most often defined as starting therapy within 8 weeks after surgery, and it reportedly reduces the risks of recurrence and increases overall survival (OS) and disease-free survival. 8, 9 Metastatic tumors may rapidly enlarge before starting chemotherapy and may lead to patient death. It is unclear whether an even earlier initiation, such as within 1 week after surgery, may provide additional improvements. We conducted a clinical trial to prevent the early growth of metastatic lesions after primary resection. Because we previously reported that early initiation of chemotherapy after surgery is feasible, 12 we evaluated its efficacy in patients subjected to colorectal surgery for symptomatic (narrowing of the stool, constipation, rectal bleeding, abdominal pain etc.) CRC with synchronous multiple distant metastases.
| MATERIALS AND METHODS

| Study design
Pearl Star 02 was a prospective, open-label, single-arm phase II trial that was completed in Japan. This study was carried out according to the ethical guidelines for clinical studies. The institutional review board at the Fukuoka University approved the protocol, and the study has been registered with the University Hospital Medical
Information Network Clinical Trials Registry (ID: UMIN000006310).
This study evaluated the efficacy of early initiation of chemotherapy after resecting colorectal cancer with distant metastases. Primary endpoint was disease control rate (DCR), whereas secondary endpoints were objective tumor response rate (RR), progression-free survival (PFS), overall survival (OS), and safety. The target sample size was 18 patients, assuming that the expected DCR and threshold DCR were 95% and 75%, respectively, with a onesided alpha level of 5% and a power of 80%. 3 | RESULTS
| Evaluation of chemotherapy
| Baseline patient characteristics
Characteristics of the study patients are presented in Table 1 . 
| Treatment
All patients successfully started chemotherapy on postoperative day 7 ( Figure 1 ). (Figure 2 ).
| Safety
Adverse events for 20 patients are summarized in Table 2 
21,22
Plasma angiopoietin-2 and vascular endothelial growth factor (VEGF) levels are significantly raised after CRC surgery. 23 Peak levels were observed during days 7-13 after surgery. The same researchers described that CRC surgery is linked to a persistent elevation in vascular cell adhesion molecule 1 (VCAM-1) levels during the first month after surgery. VCAM-1 may promote angiogenesis and chemotaxis of endothelial cells. 24 Peeters et al. 25 observed that metastasis growth is accompanied by increased cell proliferation and a significant decrease in the fraction of apoptotic cells on serial biopsies after resecting the primary tumor. The same researchers found significantly elevated cancer activity in liver metastases from CRC as measured by fluorodeoxyglucose-positron emission tomography (FDG-PET) after primary tumor resection. 18 The precise timing for starting chemotherapy prior to and/or after surgery to avoid postoperative complications is unclear, but an interval of at least 4 weeks has been proposed. In most clinical trials, patients who underwent an operation within 4 weeks were excluded. We reported a case involving the early initiation of chemotherapy on postoperative day 7 who had undergone right hemicolectomy for synchronous multiple liver, lung, and peritoneal metastases. 26 He survived without postoperative complications for 22 months despite huge liver metastases. Therefore, we carried out the present pilot study to confirm the feasibility of an immediate start for chemotherapy after surgery. future takedown of colostomy, or even death. It has been estimated that one of every three postoperative deaths after colonic surgery was because of a leaking anastomosis. 28 Several animal researchers have revealed that anastomoses were weaker and that there was a high risk of anastomotic leakage when systemic 5-FU was given as a bolus immediately after surgery. 29, 30 Immediate i.p.
5-FU also causes anastomotic leakage. 31 Continuous 5-FU infusions enabled the use of greater daily dosages and appeared safer than injecting a bolus of 5-FU. 32 Continuous infusion avoided the high serum 5-FU levels that could be observed with bolus injection dosage and may be efficacious in CRC without increasing anastomotic leakage. The oral fluoropyrimidine drug, capecitabine, evolved to ameliorate patient convenience and tolerability and has replaced continuous infusions of 5-FU in many chemotherapy regimens. 33 Capecitabine appears to be a promising substitute to continuous infusions of 5-FU, and pharmacokinetic researchers have reported that successive oral administration provided a steady-state 5-FU concentration that was comparable with that achieved by a 5 day continuous infusion. 34, 35 Furthermore, bolus 5-FU treatments led to extremely high concentrations, followed by rapid disappearance from the blood serum. 34, 35 Therefore, we chose XELOX therapy for the present study. Regarding safety, grade 3-4 fatigue was observed in 10% of patients in this study. However, this result was more frequent than the 1-3% of the SOFT study 36 and the 4-6% of the WJOG 4407G study. 37 The reason may be because of synchronous metastases, early chemotherapy initiation, or adverse events of primary tumor resection.
According to recent reports, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] OS of patients with CRC and synchronous distant metastases was 11-21 months, whereas the previously reported PFS had ranged from 5.1 to 10.5 months (Table 3) . Although our study cannot be compared with large multicenter trials, OS and PFS from this study were better than those from other studies. Therefore, early chemotherapy initiation after CRC surgery may prevent tumor growth. However, the results were obtained from the comparison with past reports using different regimens. This is a critical point for understanding the effect of early initiation of chemotherapy. Randomized controlled trials are considered essential to confirm the result. The primary CRC resection causing bleeding and severe stenosis is the first treatment step to prevent complications related to CRC. According to the Cochrane review, primary tumor resection is not associated with a consistent improvement in OS and fails to significantly reduce the risk of complications from the asymptomatic primary tumor 51 . However, our study enrolled symptomatic patients with CRC. The results will help identify answers and perform advanced trials.
To the best of our knowledge, this was the first report to determine the safety and efficacy of an early initiation of chemotherapy after resecting a primary CRC with distant synchronous metastases.
Early initiation of chemotherapy after surgery may improve the prognosis of patients with CRC having synchronous metastases. 
